VIOL Co. Ltd
Viol Co., Ltd. manufactures electrical diagnostics and medical devices. The company was founded in 2007 and is based in Seongnam, South Korea.
VIOL Co. Ltd (335890) - Net Assets
Latest net assets as of September 2025: ₩105.28 Billion KRW
Based on the latest financial reports, VIOL Co. Ltd (335890) has net assets worth ₩105.28 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩110.88 Billion) and total liabilities (₩5.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩105.28 Billion |
| % of Total Assets | 94.95% |
| Annual Growth Rate | 57.14% |
| 5-Year Change | 350.6% |
| 10-Year Change | N/A |
| Growth Volatility | 27.61 |
VIOL Co. Ltd - Net Assets Trend (2019–2024)
This chart illustrates how VIOL Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VIOL Co. Ltd (2019–2024)
The table below shows the annual net assets of VIOL Co. Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩88.82 Billion | +55.48% |
| 2023-12-31 | ₩57.12 Billion | +46.71% |
| 2022-12-31 | ₩38.94 Billion | +46.84% |
| 2021-12-31 | ₩26.52 Billion | +34.53% |
| 2020-12-31 | ₩19.71 Billion | +112.86% |
| 2019-12-31 | ₩9.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to VIOL Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7542512817000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩75.41 Billion | 84.90% |
| Common Stock | ₩5.84 Billion | 6.58% |
| Other Components | ₩7.57 Billion | 8.52% |
| Total Equity | ₩88.82 Billion | 100.00% |
VIOL Co. Ltd Competitors by Market Cap
The table below lists competitors of VIOL Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stenocare AS
CO:STENO
|
$4.04 Million |
|
Semilux International Ltd. Ordinary Shares
NASDAQ:SELX
|
$4.04 Million |
|
URU METALS LTD
F:NVRA
|
$4.04 Million |
|
Dynaciate Group Bhd
KLSE:5178
|
$4.04 Million |
|
Acrux Limited
PINK:ARUXF
|
$4.04 Million |
|
Marvel Biosciences Corp.
PINK:MBCOF
|
$4.03 Million |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
$4.03 Million |
|
Synertec Corporation Ltd
AU:SOP
|
$4.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VIOL Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,124,074,800 to 88,816,577,360, a change of 31,692,502,560 (55.5%).
- Net income of 32,640,829,630 contributed positively to equity growth.
- Dividend payments of 1,037,825,410 reduced retained earnings.
- Share repurchases of 89,497,890 reduced equity.
- New share issuances of 89,497,890 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩32.64 Billion | +36.75% |
| Dividends Paid | ₩1.04 Billion | -1.17% |
| Share Repurchases | ₩89.50 Million | -0.1% |
| Share Issuances | ₩89.50 Million | +0.1% |
| Other Changes | ₩89.50 Million | +0.1% |
| Total Change | ₩- | 55.48% |
Book Value vs Market Value Analysis
This analysis compares VIOL Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.47x to 8.13x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩1933.15 | ₩12500.00 | x |
| 2020-12-31 | ₩360.08 | ₩12500.00 | x |
| 2021-12-31 | ₩463.39 | ₩12500.00 | x |
| 2022-12-31 | ₩669.78 | ₩12500.00 | x |
| 2023-12-31 | ₩990.76 | ₩12500.00 | x |
| 2024-12-31 | ₩1538.14 | ₩12500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VIOL Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.75%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 56.09%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.10x
- Recent ROE (36.75%) is above the historical average (18.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -0.17% | 0.00% | 0.00x | 1.19x | ₩-941.53 Million |
| 2020 | -9.19% | -14.90% | 0.51x | 1.20x | ₩-3.78 Billion |
| 2021 | 16.73% | 24.15% | 0.61x | 1.13x | ₩1.79 Billion |
| 2022 | 29.47% | 36.88% | 0.70x | 1.14x | ₩7.58 Billion |
| 2023 | 37.74% | 50.71% | 0.67x | 1.12x | ₩15.85 Billion |
| 2024 | 36.75% | 56.09% | 0.59x | 1.10x | ₩23.76 Billion |
Industry Comparison
This section compares VIOL Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VIOL Co. Ltd (335890) | ₩105.28 Billion | -0.17% | 0.05x | $4.04 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |